DOXOMA-L 50MG INJ VIAL

About

DOXOMA-L 50MG INJ VIAL is a liposomal formulation of doxorubicin, an anthracycline topoisomerase inhibitor widely used in cancer chemotherapy. The liposomal encapsulation allows for a prolonged circulation time and preferential accumulation in tumor tissues due to the enhanced permeability and retention (EPR) effect, thereby increasing drug concentration at the tumor site while potentially reducing systemic toxicity, particularly cardiotoxicity and myelosuppression, compared to conventional doxorubicin. It exerts its cytotoxic effects by intercalating into DNA, inhibiting topoisomerase II, and generating free radicals, leading to DNA damage and apoptosis in rapidly dividing cancer cells. This targeted delivery system makes it a valuable option for treating various solid tumors and hematological malignancies, improving the therapeutic index for patients.

Uses

• Treatment of Kaposi's sarcoma.
• Management of ovarian cancer.
• Therapy for multiple myeloma.
• Treatment of metastatic breast cancer.

Directions For Use

Administer intravenously under the supervision of a qualified oncologist. Dosage and infusion rate are determined by the patient's condition and treatment protocol.

Benefits

• Targeted drug delivery to tumors.
• Reduced cardiotoxicity compared to conventional doxorubicin.
• Lower incidence of myelosuppression.
• Improved pharmacokinetic profile.
• Effective against various cancers.
• Enhanced patient tolerability.

Side Effects

• Nausea and vomiting
• Hair loss (alopecia)
• Myelosuppression (low blood counts)
• Stomatitis/mucositis
• Hand-foot syndrome (palmar-plantar erythrodysesthesia)
• Fatigue
• Diarrhea
• Constipation
• Anemia
• Thrombocytopenia
• Neutropenia
• Infusion-related reactions

Safety Measures

• Alcohol - Avoid alcohol during treatment as it can exacerbate liver toxicity and other side effects.
• Pregnancy - Contraindicated during pregnancy due to severe fetal harm risk; effective contraception is essential.
• Breastfeeding - Contraindicated during breastfeeding; discontinue breastfeeding due to potential harm to the infant.
• Liver - Use with extreme caution and dose adjustment in patients with hepatic impairment due to increased toxicity risk.
• Kidney - Use with caution; dose adjustments may be necessary in patients with severe renal impairment.
• Lung - Monitor for pulmonary toxicity, though less common than with conventional doxorubicin; report any respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.